National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting, 23013 [2017-10113]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 96 / Friday, May 19, 2017 / Notices
Dated: May 11, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–10153 Filed 5–18–17; 8:45 am]
Prospective Grant of Exclusive Patent
License: The Development of
Monospecific and Bispecific
Antibodies to GPC3 for the Treatment
of Human Liver Cancers
National Institutes of Health
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
ACTION:
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; NIAAA Fellowship Review.
Date: July 21, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, Terrace Level Conference Room,
5635 Fishers Lane, Bethesda, M.D 20892
Contact Person: Richard A. Rippe, Ph.D.,
Scientific Review Officer , Extramural Project
Review Branch, Office of Extramural
Activities, National Institute on Alcohol
Abuse and Alcoholism, 5635 Fishers Lane,
Room 2109, Rockville, MD 20852, 301–443–
8599, rippera@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards., National
Institutes of Health, HHS)
Dated: May 15, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–10113 Filed 5–18–17; 8:45 am]
BILLING CODE 4140–01–P
19:15 May 18, 2017
Jkt 241001
Notice.
The National Cancer Institute,
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an Exclusive Patent License to AbPro,
located in Woburn, Massachusetts, to
practice the inventions embodied in the
patent applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the NCI Technology
Transfer Center on or before June 5,
2017 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: David A. Lambertson, Ph.D.,
Senior Licensing and Patenting
Manager, NCI Technology Transfer
Center, 9609 Medical Center Drive, RM
1E530 MSC 9702, Bethesda, MD 20892–
9702 (for business mail), Rockville, MD
20850–9702, Telephone: (240)–276–
6467; Email: david.lambertson@nih.gov.
SUPPLEMENTARY INFORMATION: The
following represents the intellectual
property to be licensed under the
prospective agreement: U.S. Provisional
Patent Application 61/654,232 entitled
‘‘High-affinity Monoclonal Antibodies
To Glypican-3 And Use Thereof’’ [HHS
Ref. E–136–2012/0–US–01], PCT Patent
Application PCT/US2013/043633
entitled ‘‘High-affinity Monoclonal
Antibodies To Glypican-3 And Use
Thereof’’ [HHS Ref. E–136–2012/0–
PCT–02], Chinese Patent Application
201380039993.7 entitled ‘‘High-affinity
Monoclonal Antibodies To Glypican-3
And Use Thereof’’ [HHS Ref. E–136–
2012/0–CN–03], Japanese Patent
Application 2015–515243 entitled
‘‘High-affinity Monoclonal Antibodies
To Glypican-3 And Use Thereof’’ [HHS
Ref. E–136–2012/0–JP–04], South
Korean Patent Application 10–2014–
7037046 entitled ‘‘High-affinity
Monoclonal Antibodies To Glypican-3
And Use Thereof’’ [HHS Ref. E–136–
2012/0–KR–05], Singapore Patent
Application 11201407972R entitled
SUMMARY:
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
National Institutes of Health,
HHS.
National Institutes of Health
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
23013
‘‘High-affinity Monoclonal Antibodies
To Glypican-3 And Use Thereof’’ [HHS
Ref. E–136–2012/0–SG–06], and United
States Patent 9,409,994 entitled ‘‘Highaffinity Monoclonal Antibodies To
Glypican-3 And Use Thereof’’ [HHS Ref.
E–136–2012/0–US–07], and all
continuing U.S. and foreign patents/
patent applications for the technology
family, to AbPro. The patent rights in
these inventions have been assigned to
and/or exclusively licensed to the
Government of the United States of
America.
With respect to persons who have an
obligation to assign their right, title and
interest to the Government of the United
States of America, the patent rights in
these inventions have been assigned to
the Government of the United States of
America.
The prospective Exclusive Patent
License territory may be worldwide for
the following field of use:
The use of the YP7, YP8 and YP9.1 antiGPC3 monoclonal antibodies as monospecific
or bispecific antibodies for the treatment of
liver cancer. The licensed field of use
excludes any non-specified
immunoconjugates, including, but not
limited to, chimeric antigen receptors (CARs)
and variants thereof, Immunotoxins, and
antibody-drug conjugates (ADCs).
The present inventions to be licensed
concern monoclonal antibodies that are
specific for the cell surface domain of
GPC3: YP6, YP7, YP8, YP9 and YP9.1.
These antibodies can potentially be
used for the treatment of GPC3expressing cancers such as HCC. By
binding to and blocking GPC3 function,
these antibodies can inhibit the growth
of HCC cells, thereby decreasing the
ability of tumors to grow and
metastasize. Alternatively, the
antibodies can be used to induce
antibody-dependent anti-tumor activity
by selectively killing cells which
overexpress GPC3 while leaving
healthy, normal cells unscathed.
Finally, a secondary antibody capable of
recruiting T cells to the tumor can be
attached to the antibodies, thereby
allowing for the localization of T cells
or NK cells only to those cells which
express GPC3, similarly leading to the
selective killing of the cancer cells.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective Exclusive Patent
License will be royalty bearing and may
be granted unless within fifteen (15)
days from the date of this published
notice, the National Cancer Institute
receives written evidence and argument
that establishes that the grant of the
license would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
E:\FR\FM\19MYN1.SGM
19MYN1
]]>Agencies
[Federal Register Volume 82, Number 96 (Friday, May 19, 2017)]
[Notices]
[Page 23013]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10113]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse and Alcoholism; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Alcohol Abuse and
Alcoholism Special Emphasis Panel; NIAAA Fellowship Review.
Date: July 21, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on
Alcohol Abuse and Alcoholism, Terrace Level Conference Room, 5635
Fishers Lane, Bethesda, M.D 20892
Contact Person: Richard A. Rippe, Ph.D., Scientific Review
Officer , Extramural Project Review Branch, Office of Extramural
Activities, National Institute on Alcohol Abuse and Alcoholism, 5635
Fishers Lane, Room 2109, Rockville, MD 20852, 301-443-8599,
rippera@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.271,
Alcohol Research Career Development Awards for Scientists and
Clinicians; 93.272, Alcohol National Research Service Awards for
Research Training; 93.273, Alcohol Research Programs; 93.891,
Alcohol Research Center Grants; 93.701, ARRA Related Biomedical
Research and Research Support Awards., National Institutes of
Health, HHS)
Dated: May 15, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-10113 Filed 5-18-17; 8:45 am]
BILLING CODE 4140-01-P
